Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140928 | 1.00 | PDE4B (0.41) | PDE4BPDE4DALOX5TDP1HPGD | |
| SCHEMBL4127398 | 0.89 | ALOX5 (0.42) | PDE4BPDE4DALOX5TDP1HPGD | |
| SCHEMBL4127402 | 0.89 | ALOX5 (0.42) | PDE4BPDE4DALOX5TDP1HPGD | |
| SCHEMBL4132691 | 0.81 | KMT2A (0.46) | PDE4BPDE4DALOX5TDP1HPGD | |
| SCHEMBL4132695 | 0.81 | KMT2A (0.46) | PDE4BPDE4DALOX5TDP1HPGD | |
| SCHEMBL4140438 | 0.78 | PDE4B (0.42) | PDE4BPDE4DALOX5TDP1HPGD | |
| SCHEMBL4140435 | 0.78 | PDE4B (0.42) | PDE4BPDE4DALOX5TDP1HPGD | |
| SCHEMBL4128672 | 0.77 | PDE4B (0.35) | PDE4BPDE4DTDP1HPGDKMT2A | |
| SCHEMBL4120795 | 0.72 | ALOX5 (0.40) | PDE4BPDE4DALOX5HPGDKMT2A | |
| SCHEMBL4133913 | 0.70 | CTSA (0.36) | ALOX5TDP1HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | PDE4B 161/4885PDE4D 485/4885ALOX5 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.